		Type: Drug Guideline	Document reference: 2909	Manual Classification: Waikato DHB Drug Guidelines
Title: Dobutamine for neonates			Effective date: 26 January 2022	
Facilitator <small>sign/date</small> <i>Kerrie Knox</i> Pharmacist	Authorised <small>sign/date</small> <i>Jutta van den Boom</i> Clinical Director NICU	Authorised <small>sign/date</small> <i>John Barnard</i> Chair Medicines & Therapeutics	Version: 2	Page: 1 of 3
			Document expiry date: 26 January 2025	

© Waikato DHB, February 2022

BRIEF ADMINISTRATION GUIDE

For detailed information refer to [The Australasian Neonatal Medicines Formulary dobutamine guideline](#)



Critical Note: there are minor variations between the ANMF and Waikato DHB best practice within this drug guideline – see shaded text

Indications: To increase cardiac output by providing blood pressure support in infants with shock and hypotension. Increases contractility with little effect on rate.

Route:

- Intravenous (continuous IV infusion) via CVAD (but not via UAC)
 - Supplied as dobutamine hydrochloride, equivalent to dobutamine 250 mg/20 mL (12.5 mg/mL) ampoule
 - pH of dobutamine is 2.5 to 5.5

Dose:

- Initially 5 micrograms/kg/minute
Adjust according to response. Usual range is 2 - 25 microgram/kg/minute
Dose titrate upwards or downwards by (2-) 5 micrograms/kg/minute to achieve the target blood pressure. If the blood pressure is grossly out of range, a larger dose change will be needed. Always consider that there may be a dose delivery or preparation error if a previously stable neonate becomes suddenly unstable in the absence of any other clear cause for the change, e.g. line disconnect or obstruction, tissue line, air in line or wrong concentration of dobutamine at the time of a syringe change.

Preparation and administration

Compatible fluids: glucose 5%, glucose 10%, sodium chloride 0.9%, sodium chloride 0.45%, glucose in sodium chloride solutions

Continuous IV Infusion

- Select the concentration of dobutamine required based on the weight of the infant and in the context of any fluid restrictions (refer to appendix for assistance) and dilute the appropriate volume of dobutamine injection using compatible fluid in accordance with the table below:


Final Dobutamine Concentration	1 mg/mL 1000 microgram/mL	3 mg/mL 3000 microgram/mL	5 mg/mL 5000 microgram/mL
Volume of dobutamine (12.5 mg/mL)	4 mL	12 mL	12 mL
Volume of compatible fluid	46 mL	38 mL	18 mL
Total volume for infusion	50 mL	50 mL	30 mL

- Administer by continuous infusion (using Guardrails profile) preferably via a central line but may be used peripherally in an emergency when central access is not available.
- Do NOT flush line or suddenly stop infusion.

$$\text{Rate (mL/hr)} = \frac{60 \times \text{Dose (microgram/kg/min)} \times \text{Weight (kg)}}{\text{Concentration (microgram/mL)}}$$

Monitoring

- Continuous heart rate, blood pressure, ECG monitoring and where possible cardiac output and ventricular filling pressures. Document hourly and as required

	Document reference: 2909	Effective date: 26 Jan 2022	Expiry date: 26 Jan 2025	Page: 2 of 3
	Title: Dobutamine for neonates	Type: Drug Guideline	Version: 2	Authorising initials:

- If administering peripherally observe for injection site reactions or signs of extravasation
- Monitor urine output and fluid balance
- Observe for hypersensitivity reactions or severe adverse reactions

Storage and Stability

- Prepare a fresh solution at least every 24 hours.
- Discard ampoule once opened
- Once diluted, the solution may exhibit a pink colour which may intensify over time, but there is no significant loss of potency during the period of infusion. Discard any solutions that are hazy or contain particulate matter.

Competency for Administration

This procedure is carried out by, or under, the direct supervision of a registered nurse/registered midwife who holds current Waikato DHB Generic Medicine Management and IV certification as well as Neonatal specific competency NCV/NAC and NIC2.

Guardrails Information

Dobutamine is Guardrail profiled on the CC pump for NICU. Following are the guardrail limits:


Guardrails Drug Name	Dobutamine
Concentration (mg/mL)	
Minimum	0.6
Maximum	5
Dose rate (microgram/kg/min)	
Default	5
Soft minimum	2
Soft maximum	20
Hard max	25

References

- Australasian Neonatal Medicines Formulary (ANMF). Dobutamine 2021. Available from: https://www.seslhd.health.nsw.gov.au/sites/default/files/groups/Royal_Hospital_for_Women/Neonatal/Neomed/neomeddobutamine2021.pdf
- Max Health Ltd. Dobutamine-hameln Data Sheet. 4 April 2018. Available from: <https://www.medsafe.govt.nz/profs/datasheet/d/dobutamineHamelninf.pdf>
- Truven Health Analytics Inc. Pediatrics and Neofax®. Dobutamine monograph. Accessed 29.3.2021. Available from: <http://www.micromedexsolutions.com>.
- New Zealand Formulary for Children (NZFC). Dobutamine. Accessed 29.3.2021. Available from: https://www.nzfchildren.org.nz/nzf_1402
- Phelps SJ, Hagemann TM, Lee KR, Thompson AJ. The Teddy Bear Book: Pediatric Injectable Drugs. 11th edition. American Society of Health-System Pharmacists; 2018.
- The Royal Children's Hospital Melbourne. Paediatric Injectable Guidelines. Accessed 29.3.2021. Available from: <https://pig.rch.org.au>.
- New Zealand Hospital Pharmacists Assoc. Inc. Notes on Injectable Drugs 8th ed, 2020.
- Auckland DHB guideline Dobutamine hydrochloride for newborn intensive care. November 2011. Available from: <https://www.starship.org.nz/guidelines/dobutamine-hydrochloride-for-newborn-intensive-care/>
- Canterbury DHB Neonatal Services. Dobutamine Drug Information Sheet. March 2016. Available from: <http://www.cdhb.health.nz/Hospitals-Services/Health-Professionals/Neonatal-Clinical-Resources/Neonatal-Drug-Information-Sheets>.
- Australian Injectable Drugs Handbook 8th ed 2020. The Society of Hospital Pharmacists of Australia.

Note: Printed copies are only valid on the day of printing – they are not controlled and may not be the current version in use. Please refer to the online version.

Disclaimer: This document has been developed by Waikato District Health Board specifically for its own use. Use of this document and any reliance on the information contained therein by any third party is at their own risk and Waikato District Health Board assumes no responsibility whatsoever.

 Waikato District Health Board	Document reference: 2909	Effective date: 26 Jan 2022	Expiry date: 26 Jan 2025	Page: 3 of 3
	Title: Dobutamine for neonates		Type: Drug Guideline	Version: 2

Appendix

Infusion tables to assist concentration selection

Table 1: Infusion rates when using dobutamine concentration **1 mg/mL**
(most useful for neonates < 1 kg)

Rate (mL/hr)	0.1	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1
Weight (kg)	Approximate micrograms/kg/minute									
0.5	3	7	10	13	17	20	23	27	30	33
1	2	3	5	7	8	10	12	13	15	17
1.5	1	2	3	4	6	7	8	9	10	11
2	1	2	3	3	4	5	6	7	8	8
2.5	1	1	2	3	3	4	5	5	6	7
3	1	1	2	2	3	3	4	4	5	6
3.5	0	1	1	2	2	3	3	4	4	5

Table 2: Infusion rates when using dobutamine concentration **3 mg/mL**
(likely useful for neonates 1 – 3 kg)

Rate (mL/hr)	0.1	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1
Weight (kg)	Approximate micrograms/kg/minute									
1	5	10	15	20	25	30	35	40	45	50
1.5	3	7	10	13	17	20	23	27	30	33
2	3	5	8	10	13	15	18	20	23	25
2.5	2	4	6	8	10	12	14	16	18	20
3	2	3	5	7	8	10	12	13	15	17
3.5	1	3	4	6	7	9	10	11	13	14
4	1	3	4	5	6	8	9	10	11	13

Table 3: Infusion rates when using dobutamine concentration **5 mg/mL**
(most useful for neonates > 3 kg)

Rate (mL/hr)	0.1	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1
Weight (kg)	Approximate micrograms/kg/minute									
2	4	8	13	17	21	25	29	33	38	42
2.5	3	7	10	13	17	20	23	27	30	33
3	3	6	8	11	14	17	19	22	25	28
3.5	2	5	7	10	12	14	17	19	21	24
4	2	4	6	8	10	13	15	17	19	21
4.5	2	4	6	7	9	11	13	15	17	19
5	2	3	5	7	8	10	12	13	15	17